Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Langenbecks Arch Surg ; 406(3): 791-800, 2021 May.
Artigo em Inglês | MEDLINE | ID: mdl-33619629

RESUMO

PURPOSE: To evaluate the surgical outcomes of patients with gallbladder cancer (GBC) with jaundice due to as-yet unelucidated prognostic factors. METHODS: A total of 348 GBC patients underwent resection at our institute between 1985 and 2016. Of these, 67 had jaundice (serum total bilirubin ≥ 2 mg/dL). Preoperative biliary drainage was performed, with portal vein embolization as required. All patients underwent radical surgery. We retrospectively evaluated the outcomes, performed multivariate analysis for overall survival, and compared our findings to those reported in the literature. RESULTS: The 5-year survival rate of M0 (no distant metastasis) GBC patients with jaundice, who underwent resectional surgery, was 21.9%, versus 68.3% in those without jaundice (p < 0.05). Since 2000, surgical mortality in GBC patients with jaundice has decreased from 12 to 6.8%. Patients with jaundice had more advanced disease and underwent major hepatectomies and vascular resections; however, preoperative jaundice alone was not a prognostic factor. Multivariate analysis of jaundiced patients revealed that percutaneous biliary drainage (PTBD) (vis-à-vis endoscopic drainage [EBD], hazard ratio [HR] 2.82), postoperative morbidity (Clavien-Dindo classification ≥ 3, HR 2.31), and distant metastasis (HR 1.85) were predictors of poor long-term survival. The 5-year survival and peritoneal recurrence rates in M0 patients with jaundice were 16% and 44%, respectively, for patients with PTBD and 39% (p < 0.05) and 13% (p = 0.07) for those with EBD. CONCLUSION: M0 GBC patients with jaundice should undergo surgery if R0 resection is possible. Preoperative EBD may be superior to PTBD in M0 GBC patients with jaundice, although further studies are needed.


Assuntos
Neoplasias dos Ductos Biliares , Neoplasias da Vesícula Biliar , Icterícia , Drenagem , Neoplasias da Vesícula Biliar/complicações , Neoplasias da Vesícula Biliar/cirurgia , Humanos , Recidiva Local de Neoplasia , Estudos Retrospectivos , Taxa de Sobrevida , Resultado do Tratamento
2.
Int J Gynecol Cancer ; 23(6): 1071-7, 2013 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-23792602

RESUMO

PURPOSE: International Federation of Gynecology and Obstetrics (FIGO) staging for cervical cancer does not yet consider findings of cross-sectional imaging unlike clinical tumor, node, and metastasis (TNM) staging system. We compare the two with regard to accuracy in pretreatment staging and their reliability in the prediction of prognosis. MATERIALS AND METHODS: This was an observational study of patients with biopsy-proven nonmetastatic cervical carcinoma. Pretreatment evaluation of patients was done by clinical assessment and contrast-enhanced computed tomographic scan of the pelvis to stage the disease with FIGO and clinical TNM (cTNM) system, respectively. The extent of discordance between the 2 staging systems were studied in assessing stage of disease, correlation with histopathologic classification in patients who were operated on, and in prediction of prognosis. RESULTS: The study included 54 patients. Seventeen of 19 patients with early-stage disease underwent upfront radical surgery; and in 59% of these, FIGO did not match with final histopathologic TNM (pTNM), but only in 23% patients, cTNM did not match with histopathological TNM (P = 0.02). Sensitivity of computed tomographic scan to pick up lymph node metastasis was 85% in early disease. Stage migration rates to higher stage when considering imaging findings in stage I, stage IIA, and stage IIB were 25%, 71%, and 37%, respectively. Thirty-four percent of stage IIIB disease was downstaged with cTNM. Lymph node positivity by cTNM was a strong pointer of recurrence (P = 0.01). CONCLUSIONS: Pretreatment cross-sectional imaging may help avoid undue surgery in patients with cervical cancer with positive lymph nodes and may help in a more accurate assessment of prognosis.


Assuntos
Recidiva Local de Neoplasia/patologia , Neoplasias do Colo do Útero/classificação , Neoplasias do Colo do Útero/patologia , Adulto , Idoso , Feminino , Seguimentos , Ginecologia , Humanos , Agências Internacionais , Metástase Linfática , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Obstetrícia , Prognóstico , Estudos Prospectivos , Tomografia Computadorizada por Raios X
3.
Surgery ; 165(3): 541-547, 2019 03.
Artigo em Inglês | MEDLINE | ID: mdl-30348459

RESUMO

BACKGROUND: The treatment approach to node-positive gallbladder cancer has unresolved issues with regard to the management of patients with a positive superior retro-pancreatic (level 13a) node, which is the highest level of spread. The American Joint Committee on Cancer remains unclear on the status of the 13a node. METHODS: This retrospective study consisted of 165 patients with node-positive gallbladder cancer without distant metastasis. Patients were reclassified according to the American Joint Committee on Cancer eighth edition classification. The survival of patients with positive level 13a node was compared with that of patients with N1 disease (T stage-wise) and those with para-aortic nodal disease. A multivariate analysis was performed for factors affecting survival. RESULTS: The 5-year survival of patients with positive level 13a with 1-3 nodes was similar to those with N1 disease (40.2% and 32.9%, respectively) and was better than those with more distant nodal spread (P < .05). In univariate and multivariate analyses, intraoperative blood loss (hazard ratio [HR] 1.58), R1 resection (HR 1.87), and T4 disease (versus T2, HR 3.44) were poor prognosticators. Pancreaticoduodenectomy may be beneficial in T2 patients. CONCLUSION: A positive superior retro-pancreatic node does not worsen the prognosis in an otherwise N1 disease in T1/T2 gallbladder cancer. It behaves like a regional lymph node and should be treated as such.


Assuntos
Colecistectomia/métodos , Neoplasias da Vesícula Biliar/cirurgia , Excisão de Linfonodo/métodos , Estadiamento de Neoplasias , Pancreaticoduodenectomia/métodos , Abdome , Intervalo Livre de Doença , Feminino , Seguimentos , Neoplasias da Vesícula Biliar/mortalidade , Neoplasias da Vesícula Biliar/secundário , Humanos , Japão/epidemiologia , Linfonodos/patologia , Metástase Linfática , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Taxa de Sobrevida/tendências
4.
Asia Pac J Clin Oncol ; 9(1): 47-52, 2013 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-22974267

RESUMO

AIM: Comorbidity in cancer patients may influence treatment decisions, postoperative morbidity and ultimately, survival. The TNM staging system does not take comorbidity into account. This study investigates the burden of comorbidity in cancer patients, its effect on resection rate, postoperative morbidity, adjuvant therapy, recurrence and survival. METHODS: This prospective cohort study included 358 patients with potentially operable cancer. Pretreatment comorbidity was assessed using a modified Kaplan-Feinstein index (adult comorbidity evaluation-27) and its influence on resection rate and postoperative adjuvant therapy was assessed. The comorbidity grade was consolidated with TNM stage into four distinct groups that were compared for differences in the incidence of postoperative complications, duration of hospital stay, 30-day mortality, recurrence and survival. RESULTS: Cardiovascular diseases including hypertension (27%) and diabetes mellitus (12%) were the most common comorbidities. Comorbidity did not influence the resection rate, but affected adjuvant treatment (P < 0.01). There was a greater incidence of postoperative local and systemic complications and duration of hospital stay in patients with comorbidity. Recurrence rates were unaffected. Mortality in patients with comorbidity was greater, especially postoperative 30-day mortality, but this was statistically insignificant. CONCLUSION: Comorbidity increases postoperative morbidity and affects adjuvant therapy, although the resection rate is not influenced. The greater percentage of deaths in patients with comorbidity warrants further studies. Recurrence rates remain unaffected. However, a longer period of follow up is needed for a clearer picture.


Assuntos
Doenças Cardiovasculares/etiologia , Comorbidade , Tomada de Decisões , Diabetes Mellitus/etiologia , Hipertensão/etiologia , Recidiva Local de Neoplasia/epidemiologia , Neoplasias/epidemiologia , Complicações Pós-Operatórias , Adulto , Doenças Cardiovasculares/diagnóstico , Diabetes Mellitus/diagnóstico , Seguimentos , Humanos , Hipertensão/diagnóstico , Índia/epidemiologia , Tempo de Internação , Recidiva Local de Neoplasia/mortalidade , Recidiva Local de Neoplasia/patologia , Recidiva Local de Neoplasia/cirurgia , Estadiamento de Neoplasias , Neoplasias/mortalidade , Neoplasias/patologia , Neoplasias/cirurgia , Período Pós-Operatório , Prognóstico , Estudos Prospectivos , Fatores de Risco , Taxa de Sobrevida , Centros de Atenção Terciária
5.
Cases J ; 1(1): 118, 2008 Aug 21.
Artigo em Inglês | MEDLINE | ID: mdl-18718001

RESUMO

A middle age lady presented with abdominal pain was diagnosed to have multiple peritoneal and hepatic hydatid cysts on CT scan. Retrospectively she was found to have suffered blunt abdominal trauma.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA